Erratum for the research article “The suppressive efficacy of THZ1 depends on KRAS mutation subtype and is associated with super-enhancer activity and the PI3K/AKT/mTOR signalling in pancreatic ductal adenocarcinoma: A hypothesis-generating study” by Huang et al

Lei Huang; Hui Yang; Kaidi Chen; Jing Yuan; Jie Li; Guanghai Dai; Mancang Gu; Yan Shi

doi:10.1002/ctm2.70158

Clinical and Translational Medicine ›› 2025, Vol. 15 ›› Issue (1) : e70158 DOI: 10.1002/ctm2.70158

LETTER TO THE JOURNAL

Erratum for the research article “The suppressive efficacy of THZ1 depends on KRAS mutation subtype and is associated with super-enhancer activity and the PI3K/AKT/mTOR signalling in pancreatic ductal adenocarcinoma: A hypothesis-generating study” by Huang et al

Lei Huang ¹^,^†
, Hui Yang ¹
, Kaidi Chen ²
, Jing Yuan ³
, Jie Li ³
, Guanghai Dai ⁴^,^†
, Mancang Gu ²^,⁵^,^†
, Yan Shi ⁶^,^†

Author information +

History +

PDF

Cite this article

Download citation ▾

Lei Huang, Hui Yang, Kaidi Chen, Jing Yuan, Jie Li, Guanghai Dai, Mancang Gu, Yan Shi. Erratum for the research article “The suppressive efficacy of THZ1 depends on KRAS mutation subtype and is associated with super-enhancer activity and the PI3K/AKT/mTOR signalling in pancreatic ductal adenocarcinoma: A hypothesis-generating study” by Huang et al. Clinical and Translational Medicine, 2025, 15(1): e70158 DOI:10.1002/ctm2.70158

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Huang L, Yang H, Chen K, et al. The suppressive efficacy of THZ1 depends on KRAS mutation subtype and is associated with super-enhancer activity and the PI3K/AKT/mTOR signalling in pancreatic ductal adenocarcinoma: a hypothesis-generating study. Clin Transl Med. 2023;13(12):e1500.

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.